Key Findings:
- Clinico-genomic analyses of tumors from patients with RET-rearranged advanced NSCLC treated with selective RET inhibitors demonstrated correlations between outcomes and genomic features.
- TP53 co-mutation was associated with shorter progression-free and overall survival, indicating adverse prognostic significance.
- RET fusion partner was associated with differences in clinical outcomes.